Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.88 USD
+0.20 (1.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum F VGM
Roivant Sciences Ltd. (ROIV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.89 | $22.00 | $12.00 | 44.61% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Roivant Sciences Ltd. comes to $16.89. The forecasts range from a low of $12.00 to a high of $22.00. The average price target represents an increase of 44.61% from the last closing price of $11.68.
Analyst Price Targets (9 )
Broker Rating
Roivant Sciences Ltd. currently has an average brokerage recommendation (ABR) of 1.18 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.18 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, 10 are Strong Buy, representing 90.91% of all recommendations. A month ago, Strong Buy represented 90.91%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ROIV.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/19/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
8/12/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
7/26/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
6/18/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
4/3/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
2/15/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
11/15/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.18 |
ABR (Last week) | 1.18 |
# of Recs in ABR | 11 |
Average Target Price | $16.89 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.21 |